collection
MENU ▼
Read by QxMD icon Read
search

Spondyloarthritis

shared collection
26 papers 0 to 25 followers
https://www.readbyqxmd.com/read/28521047/musculoskeletal-ultrasonography-for-psoriatic-arthritis-and-psoriasis-patients-a-systematic-literature-review
#1
Alen Zabotti, Francesca Bandinelli, Alberto Batticciotto, Carlo Alberto Scirè, Annamaria Iagnocco, Garifallia Sakellariou
Objective.: To systematically review the role of musculoskeletal US in patients suffering from PsA or psoriasis (Pso) in terms of prevalence, diagnosis, prognosis, monitoring and treatment. Methods.: A systematic literature review was conducted through medical databases (MEDLINE via PubMed, Embase) and the grey literature up to September 2015 to inform a new study of the Musculoskeletal Ultrasound Study Group of the Italian Society for Rheumatology. All articles reporting data on musculoskeletal US in PsA or Pso were included and extracted according to the underlying clinical question...
May 18, 2017: Rheumatology
https://www.readbyqxmd.com/read/28446810/pathogenesis-of-ankylosing-spondylitis-recent-advances-and-future-directions
#2
REVIEW
Vidya Ranganathan, Eric Gracey, Matthew A Brown, Robert D Inman, Nigil Haroon
Over the past 5 years, advances in high-throughput techniques and studies involving large cohorts of patients have led to considerable advances in the identification of novel genetic associations and immune pathways involved in ankylosing spondylitis (AS). These discoveries include genes encoding cytokine receptors, transcription factors, signalling molecules and transport proteins. Although progress has been made in understanding the functions and potential pathogenic roles of some of these molecules, much work remains to be done to comprehend their complex interactions and therapeutic potential in AS...
June 2017: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/28363434/switching-biologics-in-the-treatment-of-psoriatic-arthritis
#3
REVIEW
Joseph F Merola, Benjamin Lockshin, Elinor A Mody
OBJECTIVE: Psoriatic arthritis (PsA) is a heterogeneous inflammatory disorder that requires targeted treatment based on clinical manifestations, symptom severity, comorbidities, and other factors. Moderate or severe peripheral arthritis symptoms are typically treated with disease-modifying antirheumatic drugs (DMARDs) or biologic DMARDs (bDMARDs), and early and aggressive treatment is recommended in order to prevent permanent damage. Although rheumatologists are now able to choose between several bDMARDs for PsA that have different chemical structures, pharmacokinetic properties, dosing regimens, immunogenicity, safety profiles, and mechanisms of action, there is a lack of typical patient profiles or detailed treatment algorithms that can be followed when patients require alterations in their therapeutic regimens...
February 8, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28213565/anti-tnf-induced-remission-in-very-early-peripheral-spondyloarthritis-the-crespa-study
#4
Philippe Carron, Gaëlle Varkas, Heleen Cypers, Liesbet Van Praet, Dirk Elewaut, Filip Van den Bosch
OBJECTIVE: To evaluate the efficacy and safety of golimumab to induce clinical remission in patients with very early, active peripheral spondyloarthritis (pSpA). METHODS: Clinical REmission in peripheral SPondyloArthritis is a monocentric study of golimumab treatment in patients with pSpA. All patients fulfilled the Assessment of SpondyloArthritis international Society classification criteria for pSpA, with a symptom duration ≤12 weeks. Patients were randomised 2:1 to receive golimumab 50 mg every 4 weeks or matching placebo for 24 weeks...
February 17, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28254789/tumour-necrosis-factor-inhibitor-treatment-and-occurrence-of-anterior-uveitis-in-ankylosing-spondylitis-results-from-the-swedish-biologics-register
#5
Elisabeth Lie, Ulf Lindström, Tatiana Zverkova-Sandström, Inge C Olsen, Helena Forsblad-d'Elia, Johan Askling, Meliha C Kapetanovic, Lars Erik Kristensen, Lennart T H Jacobsson
OBJECTIVES: Tumour necrosis factor-α inhibitor (TNFi) treatment has been shown to reduce the rates of anterior uveitis (AU) in patients with ankylosing spondylitis (AS). Our objective was to compare the effect of adalimumab (ADA), etanercept (ETN) and infliximab (IFX) on AU occurrence in AS, using real-world data. METHODS: Patients with AS starting ADA, ETN or IFX as their first TNFi from January 2003 to December 2010 were extracted from the Swedish Rheumatology Quality Register...
March 2, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28283515/comparison-of-mri-with-radiography-for-detecting-structural-lesions-of-the-sacroiliac-joint-using-ct-as-standard-of-reference-results-from-the-simact-study
#6
Torsten Diekhoff, Kay-Geert A Hermann, Juliane Greese, Carsten Schwenke, Denis Poddubnyy, Bernd Hamm, Joachim Sieper
OBJECTIVE: Radiographs of sacroiliac (SI) joints are used for the detection of structural damage in patients with axial spondyloarthritis (axSpA), but are often difficult to interpret. Here, we address the question how the T1-weighted MRI (T1w MRI) sequence compares with radiography for SI joints' structural lesions using low-dose CT as the standard of reference. METHODS: Radiographs, T1w MRI and low-dose CT of the SI joints from 110 patients (mean age 36.1 (19-57) years, 52% males and 48% females; 53% with axSpA, 21 non-radiographic axSpA and 32% radiographic axSpA, 47% with non-SpA) referred to the rheumatologist because of unclear chronic back pain, but possible axSpA, were scored for structural lesions (erosions, sclerosis, joint space changes and an overall impression of positivity)...
March 10, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28130206/tofacitinib-in-patients-with-ankylosing-spondylitis-a-phase-ii-16-week-randomised-placebo-controlled-dose-ranging-study
#7
Désirée van der Heijde, Atul Deodhar, James C Wei, Edit Drescher, Dona Fleishaker, Thijs Hendrikx, David Li, Sujatha Menon, Keith S Kanik
OBJECTIVES: To compare efficacy and safety of various doses of tofacitinib, an oral Janus kinase inhibitor, with placebo in patients with active ankylosing spondylitis (AS, radiographic axial spondyloarthritis). METHODS: In this 16-week (12-week treatment, 4-week washout), phase II, multicentre, dose-ranging trial, adult patients with active AS were randomised (N=51, 52, 52, 52, respectively) to placebo or tofacitinib 2, 5 or 10 mg twice daily. The primary efficacy endpoint was Assessment of SpondyloArthritis International Society 20% improvement (ASAS20) response rate at week 12...
January 27, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28119289/synovial-features-of-patients-with-rheumatoid-arthritis-and-psoriatic-arthritis-in-clinical-and-ultrasound-remission-differ-under-anti-tnf-therapy-a-clue-to-interpret-different-chances-of-relapse-after-clinical-remission
#8
Stefano Alivernini, Barbara Tolusso, Luca Petricca, Laura Bui, Gabriele Di Sante, Giusy Peluso, Roberta Benvenuto, Anna Laura Fedele, Franco Federico, Gianfranco Ferraccioli, Elisa Gremese
OBJECTIVE: To define the synovial characteristics of patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) in clinical and ultrasound remission achieved by combination therapy with methotrexate (MTX) and tumour necrosis factor (TNF) blockers. METHODS: Patients with RA in remission (n=25) (disease activity score (DAS)<1.6 for at least 6 months), patients with RA in low disease activity (LDA) (n=10) (1.6<DAS<2.4 for at least 6 months) and patients with PsA in remission (n=18) (DAS<1...
January 24, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28110981/axial-spondyloarthritis
#9
REVIEW
Joachim Sieper, Denis Poddubnyy
The term axial spondyloarthritis covers both patients with non-radiographic and radiographic axial spondyloarthritis, which is also termed ankylosing spondylitis. The disease usually starts in the third decade of life with a male to female ratio of two to one for radiographic axial spondyloarthritis and of one to one for non-radiographic axial spondyloarthritis. More than 90% heritabilty has been estimated, the highest genetic association being with HLA-B27. The pathogenic role of HLA-B27 is still not clear although various hypotheses are available...
January 19, 2017: Lancet
https://www.readbyqxmd.com/read/28087505/2016-update-of-the-asas-eular-management-recommendations-for-axial-spondyloarthritis
#10
Désirée van der Heijde, Sofia Ramiro, Robert Landewé, Xenofon Baraliakos, Filip Van den Bosch, Alexandre Sepriano, Andrea Regel, Adrian Ciurea, Hanne Dagfinrud, Maxime Dougados, Floris van Gaalen, Pál Géher, Irene van der Horst-Bruinsma, Robert D Inman, Merryn Jongkees, Uta Kiltz, Tore K Kvien, Pedro M Machado, Helena Marzo-Ortega, Anna Molto, Victoria Navarro-Compàn, Salih Ozgocmen, Fernando M Pimentel-Santos, John Reveille, Martin Rudwaleit, Jochen Sieper, Percival Sampaio-Barros, Dieter Wiek, Jürgen Braun
To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with axSpA. Following the latest version of the European League Against Rheumatism (EULAR) Standardised Operating Procedures, two systematic literature reviews first collected the evidence regarding all treatment options (pharmacological and non-pharmacological) that were published since 2009...
June 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28052860/increased-prevalence-of-coronary-plaque-in-patients-with-psoriatic-arthritis-without-prior-diagnosis-of-coronary-artery-disease
#11
Jiayun Shen, Ka-Tak Wong, Isaac T Cheng, Qing Shang, Edmund K Li, Priscilla Wong, Emily W Kun, Mei Yan Law, Ronald Yip, Isaac Yim, Shirley Ying, Martin Li, Tena K Li, Chun-Kwok Wong, Tracy Y Zhu, Jack Jock-Wai Lee, Mimi Chang, Alex Pui-Wai Lee, Lai-Shan Tam
OBJECTIVES: To evaluate coronary atherosclerosis in patients with psoriatic arthritis (PsA) and control subjects using coronary CT angiography (CCTA). METHODS: Ninety consecutive patients with PsA (male: 56(62.2%); 50.3±11.1 years) were recruited. 240 controls (male: 137(57.1%); 49.6±10.7 years) without known cardiovascular (CV) diseases who underwent CCTA due to chest pain and/or multiple CV risk factors were recruited for comparison. RESULTS: Patients with PsA and controls were matched in age, gender and traditional CV risk factors (all p>0...
January 4, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27974094/long-term-safety-of-anti-tnf-agents-on-the-liver-of-patients-with-spondyloarthritis-and-potential-occult-hepatitis-b-viral-infection-an-observational-multicentre-study
#12
MULTICENTER STUDY
Chiara Giannitti, Giuseppe Lopalco, Antonio Vitale, Donato Rigante, Maria Grazia Anelli, Marta Fabbroni, Stefania Manganelli, Mauro Galeazzi, Bruno Frediani, Michele Barone, Giovanni Lapadula, Florenzo Iannone, Luca Cantarini
OBJECTIVES: The aim of the study was to retrospectively evaluate the long-term safety profile of anti-tumour necrosis factor (TNF)-α agents on the liver of patients with spondyloarthritis (SpA) and a previously resolved hepatitis B virus (HBV) infection. METHODS: Medical records from 992 consecutive outpatients receiving anti-TNF-α therapy between 2007 and 2015 were retrospectively reviewed. HBV infection was assessed evaluating HBV surface antigen (HBsAg), antibodies to HBsAg (anti-HBs), antibodies to hepatitis B core (anti-HBc), and HBV-DNA levels...
January 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27222669/cardiac-involvement-in-ankylosing-spondylitis
#13
REVIEW
Yasemin Ozkan
Ankylosing spondylitis is one of the subgroup of diseases called "seronegative spondyloarthropathy". Frequently, it affects the vertebral colon and sacroiliac joint primarily and affects the peripheral joints less often. This chronic, inflammatory and rheumatic disease can also affect the extraarticular regions of the body. The extraarticular affections can be ophthalmologic, cardiac, pulmonary or neurologic. The cardiac affection can be 2-10% in all patients. Cardiac complications such as left ventricular dysfunction, aortitis, aortic regurgitation, pericarditis and cardiomegaly are reviewed...
June 2016: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/26998860/anti-tnf-discontinuation-and-tapering-strategies-in-patients-with-axial-spondyloarthritis-a-systematic-literature-review
#14
REVIEW
Victoria Navarro-Compán, Chamaida Plasencia-Rodríguez, Eugenio de Miguel, Alejandro Balsa, Emilio Martín-Mola, Daniel Seoane-Mato, Juan D Cañete
OBJECTIVE: The aim was to evaluate whether anti-TNF discontinuation and tapering strategies are efficacious for maintaining remission or low disease activity (LDA) in patients with axial spondyloarthritis. METHODS: A systematic literature review up to September 2014 was performed using Medline, EMBASE and Cochrane databases. Longitudinal studies evaluating the efficacy of discontinuation/tapering of anti-TNF therapy to maintain clinical response achieved after receiving a standard dose of the same drug were included...
July 2016: Rheumatology
https://www.readbyqxmd.com/read/27884254/troponin-testing-for-clinicians
#15
REVIEW
John E Brush, Sanjay Kaul, Harlan M Krumholz
The analytical performance of troponin assays has improved markedly in the last 2 decades. The variety of assays, their evolution over time, and their critical importance in influencing care, mandates the need for skills in their use. There are 3 critical elements necessary for optimal use of troponin testing in clinical care, as follows: 1) the analytical performance of the assay; 2) the clinical sensitivity and specificity of the test result; and 3) the clinical reasoning for ordering and the proper clinical context for interpreting the test result...
November 29, 2016: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/27913376/axial-disease-in-psoriatic-arthritis-study-defining-the-clinical-and-radiographic-phenotype-of-psoriatic-spondyloarthritis
#16
COMPARATIVE STUDY
Deepak R Jadon, Raj Sengupta, Alison Nightingale, Mark Lindsay, Eleanor Korendowych, Graham Robinson, Amelia Jobling, Gavin Shaddick, Jing Bi, Robert Winchester, Jon T Giles, Neil J McHugh
OBJECTIVES: To compare the prevalence, clinical and radiographic characteristics of psoriatic spondyloarthritis (PsSpA) in psoriatic arthritis (PsA), with ankylosing spondylitis (AS). METHODS: A prospective single-centre cross-sectional observational study recruited consecutive PsA and AS cases. Participants completed outcome measures, and underwent clinical examination, axial radiographic scoring and HLA-sequencing. Multivariable analyses are presented. RESULTS: The 402 enrolled cases (201 PsA, 201 AS; fulfilling classification criteria for respective conditions) were reclassified based upon radiographic axial disease and psoriasis, as: 118 PsSpA, 127 peripheral-only PsA (pPsA), and 157 AS without psoriasis (AS) cases...
April 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27908311/obesity-decreases-clinical-efficacy-and-levels-of-adalimumab-in-patients-with-ankylosing-spondylitis
#17
José Rosas, Francisca Llinares-Tello, José Miguel Senabre-Gallego, Xavier Barber-Vallés, Gregorio Santos-Soler, Esteban Salas-Heredia, Ana Pons Bas, Catalina Cano Pérez, Mario García-Carrasco
OBJECTIVES: Obesity can be a factor that affects response to anti-TNF drugs. However, studies on patients with ankylosing spondylitis (AS) are rare. We aimed to determine whether obesity affects serum levels of adalimumab (ADL), and immunogenicity and clinical efficacy of the drug in patients with AS. METHODS: A cross-sectional study on 57 patients with axial AS receiving ADL was conducted. They received DMARD per standard of care at their rheumatologist's discretion...
January 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27829672/management-of-psoriatic-arthritis-in-2016-a-comparison-of-eular-and-grappa-recommendations
#18
REVIEW
Laure Gossec, Laura C Coates, Maarten de Wit, Arthur Kavanaugh, Sofia Ramiro, Philip J Mease, Christopher T Ritchlin, Désirée van der Heijde, Josef S Smolen
Psoriatic arthritis (PsA) is a heterogeneous, potentially severe disease. Many therapeutic agents are now available for PsA, but treatment decisions are not always straightforward. To assist in this decision making, two sets of recommendations for the management of PsA were published in 2016 by international organizations - the European League Against Rheumatism (EULAR) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). In both sets of recommendations, the heterogeneity of PsA is recognized and the place of various drugs in the therapeutic armamentarium is discussed...
December 2016: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/27558584/bsr-and-bhpr-guideline-for-the-treatment-of-axial-spondyloarthritis-including-ankylosing-spondylitis-with-biologics
#19
REVIEW
Louise Hamilton, Nick Barkham, Ashok Bhalla, Robin Brittain, Debbie Cook, Gareth Jones, Kirsten Mackay, David Marshall, Helena Marzo-Ortega, Daniel Murphy, Claire Riddell, Raj Sengupta, Stefan Siebert, Liz Van Rossen, Karl Gaffney
No abstract text is available yet for this article.
February 2017: Rheumatology
https://www.readbyqxmd.com/read/27411482/partial-remission-in-ankylosing-spondylitis-and-non-radiographic-axial-spondyloarthritis-in-treatment-with-infliximab-plus-naproxen-or-naproxen-alone-associations-between-partial-remission-and-baseline-disease-characteristics
#20
Joachim Sieper, Martin Rudwaleit, Jan Lenaerts, Jürgen Wollenhaupt, Leysan Myasoutova, Sung-Hwan Park, Yeong W Song, Ruji Yao, Susan Huyck, Marinella Govoni, Denesh Chitkara, Nathan Vastesaeger
OBJECTIVES: To evaluate partial remission during treatment with infliximab (IFX) + naproxen (NPX) vs NPX alone in patients from the two subgroups of SpA and explore baseline predictors of partial remission. METHODS: Infliximab as First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial was a double-blind, randomised controlled trial of IFX in biologic-naïve patients with early, active axial SpA. Patients were randomised (2:1) to receive 28 weeks of treatment with i...
November 2016: Rheumatology
label_collection
label_collection
8012
1
2
2016-10-08 16:41:49
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"